BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, November 29, 2023
See today's BioWorld
Home
» Biogen brings FA drug into the fold with $7.3B Reata acquisition
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Biogen brings FA drug into the fold with $7.3B Reata acquisition
July 28, 2023
By
Lee Landenberger
No Comments
In the second-biggest M&A deal so far in 2023, Biogen Inc. plans to acquire Reata Pharmaceuticals Inc. for an enterprise value of about $7.3 billion.
BioWorld
Deals and M&A
Acquisition
